Grail (NASDAQ:GRAL) Earns Peer Perform Rating from Analysts at Wolfe Research

Investment analysts at Wolfe Research assumed coverage on shares of Grail (NASDAQ:GRAL) in a research note issued to investors on Friday,Briefing.com Automated Import reports. The brokerage set a “peer perform” rating on the stock.

Separately, Guggenheim initiated coverage on shares of Grail in a research report on Thursday, October 17th. They set a “neutral” rating on the stock.

Grail Stock Performance

Grail stock opened at $15.81 on Friday. Grail has a 12 month low of $12.33 and a 12 month high of $23.36. The company has a 50 day moving average price of $13.74.

Grail (NASDAQ:GRAL) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($5.30) earnings per share for the quarter. The business had revenue of $31.97 million during the quarter.

Insider Buying and Selling

In other news, CEO Robert P. Ragusa sold 123,454 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the completion of the transaction, the chief executive officer now directly owns 612,661 shares in the company, valued at approximately $8,589,507.22. This represents a 16.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Chun R. Ding acquired 35,000 shares of the stock in a transaction dated Thursday, October 3rd. The stock was purchased at an average cost of $12.71 per share, with a total value of $444,850.00. Following the purchase, the insider now directly owns 3,558,655 shares of the company’s stock, valued at $45,230,505.05. This trade represents a 0.99 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 58,829 shares of company stock worth $757,298.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.